Signia Therapeutics

SIGNIA THERAPEUTICS proposes a breakthrough strategy to repurpose rapidly & at low cost marketed drugs or to recycle drugs for new antiviral indication against respiratory viruses. Signia Therapeutic’s drug discovery platform has demonstrated its potential with POC established for FDA-approved drugs that were validated for anti-influenza & anti-MERS-CoV indications. Signia Therapeutics has a further validation of its development strategy through the clinical evaluation of repurposed drugs as new effective antivirals. A phase 2b clinical trial started in Dec. 2017 in order to evaluate 2 of Signia’s antiviral candidates against influenza. This clinical trial will enroll 300 severe Flu patients with final results in Q2 2019. This milestone confirms Signia’s strategy & validates its proprietary discovery platform.